INSTITUTO DE INVESTIGACIÓN BIOMÉDICA DE SALAMANCA
Instituto
University of Oslo
Oslo, NoruegaPublicaciones en colaboración con investigadores/as de University of Oslo (43)
2024
-
Melflufen in relapsed/refractory multiple myeloma refractory to prior alkylators: A subgroup analysis from the OCEAN study
European Journal of Haematology, Vol. 112, Núm. 3, pp. 402-411
-
ModelViz: A Model-Driven Engineering Approach for Visual Analytics System Design
IEEE Access, Vol. 12, pp. 42667-42682
2023
-
A second update on mapping the human genetic architecture of COVID-19
Nature
-
Benefit Versus Risk Assessment of Melflufen and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Analyses From Longer Follow-up of the OCEAN and HORIZON Studies
Clinical Lymphoma, Myeloma and Leukemia, Vol. 23, Núm. 9, pp. 687-696
-
DCServCG: A data-centric service code generation using deep learning
Engineering Applications of Artificial Intelligence, Vol. 123
-
Industrial data monetization: A blockchain-based industrial IoT data trading system
Internet of Things (Netherlands), Vol. 24
-
Liquid biopsy-based protein biomarkers for risk prediction, early diagnosis, and prognostication of cholangiocarcinoma
Journal of Hepatology, Vol. 79, Núm. 1, pp. 93-108
-
Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network
The Lancet Oncology, Vol. 24, Núm. 6, pp. e255-e269
-
siRNA screening reveals that SNAP29 contributes to exosome release
Cellular and Molecular Life Sciences, Vol. 80, Núm. 7
2022
-
Corrigendum: “Corrigendum to ‘Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up’”: (Annals of Oncology (2022) 33(1) (117), (S0923753421044999), (10.1016/j.annonc.2021.10.001))
Annals of Oncology
-
Effects of copy number variations on brain structure and risk for psychiatric illness: Large-scale studies from the ENIGMA working groups on CNVs
Human Brain Mapping, Vol. 43, Núm. 1, pp. 300-328
-
Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 study
The Lancet Haematology, Vol. 9, Núm. 2, pp. e98-e110
-
Novel genes and sex differences in COVID-19 severity
Human molecular genetics, Vol. 31, Núm. 22, pp. 3789-3806
2021
-
1q21.1 distal copy number variants are associated with cerebral and cognitive alterations in humans
Translational psychiatry, Vol. 11, Núm. 1, pp. 182
-
COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network
The Lancet Haematology, Vol. 8, Núm. 12, pp. e934-e946
-
Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1
Autophagy, Vol. 17, Núm. 1, pp. 1-382
-
Multiple Myeloma: EHA-ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up
HemaSphere, Vol. 5, Núm. 2
-
Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†
Annals of Oncology, Vol. 32, Núm. 3, pp. 309-322
2020
-
Association of Copy Number Variation of the 15q11.2 BP1-BP2 Region with Cortical and Subcortical Morphology and Cognition
JAMA Psychiatry, Vol. 77, Núm. 4, pp. 420-430
-
Dose response of the 16p11.2 distal copy number variant on intracranial volume and basal ganglia
Molecular Psychiatry, Vol. 25, Núm. 3, pp. 584-602